Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Relief Therapeutics Receives $2M Milestone Payment Following FDA Approval | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Relief Therapeutics Receives $2M Milestone Payment Following FDA Approval

The payment is part of the previously announced royalty monetization agreement between Relief and SWK.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Relief Therapeutics Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, will receive a $2 million milestone payment from SWK Funding LLC (SWK) this month, following the U.S. Food and Drug Administration’s (FDA) approval of Zevra Therapeutics Inc.’s arimoclomol for the treatment of Niemann-Pick Disease Type C.
 
The first NPC drug approved by the FDA, MIPLYFFA (arimoclomol) is indicated for use in combination with miglustat for the treatment of neurological manifestations of NPC in adult and pediatric patients 2 years of age and older.
 
The payment is part of the previously announced royalty monetization agreement between Relief and SWK. Under this agreement, Relief received an initial $5.75 million in August 2024 and is eligible to receive up to an additional $5.25 million contingent on specific milestones. With the FDA’s approval of arimoclomol, the first $2 million milestone has now been successfully met. Relief remains eligible for $3.25 million if OLPRUVA’s quarterly net sales reach $1.5 million by the end of the third quarter of 2025.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters